Anti iTCR/anti-HER2 bispecific MAIT-cell engager (Biomunex Pharmaceuticals/Universitätsklinikum Schleswig-Holstein/University of Montpellier)

N/A

Report date: 2026/03/24 20:00:35

Base Information

Drug NameAnti iTCR/anti-HER2 bispecific MAIT-cell engager (Biomunex Pharmaceuticals/Universitätsklinikum Schleswig-Holstein/University of Montpellier)
Drug Alias Nameanti iTCR/anti-HER2 bispecific mucosal associated invariant T-cell engager (Biomunex Pharmaceuticals/ Universitätsklinikum Schleswig-Holstein/ University of Montpellier)BMX-A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulatorsT-cell receptor modulatorsT lymphocytes stimulants +[4] 
TargetsT-cell receptorReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermanyFrance
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversitätsklinikum Schleswig-HolsteinBiomunex Pharmaceuticals IncUniversity of Montpellier
China Registration ClassN/A

Develop Information

Active CompaniesUniversitätsklinikum Schleswig-HolsteinUniversity of MontpellierBiomunex Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A